Stocktoria
BioRestorative Therapies, Inc. BRTX
Nasdaq · XNAS · stock · Services-Misc Health & Allied Services, NEC · website · IPO 2001-07-11
BioRestorative Therapies, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $359,700 | $401,000 | $145,800 | $119,800 | $46,000 |
| Gross profit | $335,856 | $372,928 | $145,800 | — | — |
| R&D expense | $10.1M | $6.7M | $4.0M | $3.5M | $729,058 |
| Operating income | -$15.6M | -$11.6M | -$15.2M | -$19.0M | -$26.3M |
| Net income | -$14.2M | -$9.0M | -$10.4M | -$18.5M | -$44.3M |
| EPS (diluted) | $-1.58 | $-1.16 | $-2.47 | $-5.11 | — |
| Operating cash flow | -$10.8M | -$8.2M | -$6.4M | -$5.9M | -$3.3M |
| Free cash flow | -$10.9M | -$8.3M | -$6.6M | -$6.2M | -$3.4M |
| Cash & equivalents | $1.5M | $547,890 | $884,377 | $1.7M | $21.0M |
| Total assets | $4.1M | $12.3M | $12.6M | $16.4M | $22.5M |
| Total liabilities | — | $3.7M | $2.6M | $602,619 | $856,497 |
| Shareholders' equity | $356,744 | $8.5M | $10.0M | $10.3M | $21.6M |
Source: SEC EDGAR filings · CIK 0001505497 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.